Received Apr 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 37F34 | — |
Administration after temperature excursion; Administration under the recommended age; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 7-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 37F34, expiry date 24-OCT-2027) for prophylaxis. On an unknown date, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: Administration after temperature excursion) and inappropriate age at vaccine administration (Verbatim: Administration under the recommended age). The outcome of the incorrect storage of drug and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 09-APR-2026 A healthcare professional called in to initially report that their GSK vaccines had unfortunately been exposed to a temperature excursion. The initial call in case was being processed, but they called in a few minutes later, stating that they actually also wanted to report that two patients received some of the doses there had been exposed to the temperature excursion. This case US2026048985 reported by same reporter.; Sender's Comments: US-GSK-US2026048985:SAME REPORTER